Dupilumab: A Potential Option for Young Children With Alopecia Areata and Atopic Features
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/4728080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 22.06.2026. Verfasst von Ying Gu und 1 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Beijing Municipal Education Commission.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Alopecia areata (AA) frequently coexists with atopic disorders in children, suggesting a potential role for Type 2 inflammation in disease pathogenesis. However, evidence supporting biologic therapy for very young children with AA remains limited.
Objective
To evaluate the clinical response and safety of dupilumab in young children with AA and atopic features.
Methods
We retrospectively reviewed children aged 1–11 years with AA who received dupilumab while continuing background topical therapies at Beijing Children’s Hospital. Disease severity was assessed using the Severity of Alopecia Tool (SALT). Peripheral eosinophil counts, total serum IgE, and allergen‐specific IgE levels were retrieved from available laboratory records before and during treatment.
Results
Ten patients (6 boys and 4 girls) were included. The median age was 4.4 years (range: 1.5–10.9 years), and the median age of disease onset of 2.6 years (range: 4 months–5 years). Early hair regrowth was observed following dupilumab initiation, with progressive improvement over time. Complete hair regrowth was achieved in all patients within this cohort during follow‐up. Total and allergen‐specific IgE levels declined during treatment. Two patients experienced transient relapse after upper respiratory infection but responded to continued therapy. No serious adverse events were observed.
Conclusion
In this small retrospective cohort, dupilumab was associated with favorable outcomes in pediatric AA with atopic features, although these findings should be interpreted cautiously.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Beijing Municipal Education Commission
- Beijing Hospital Authority
Zitieren
APA
Gu, Y., & Zhang, B. (2026). Dupilumab: A Potential Option for Young Children With Alopecia Areata and Atopic Features. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/4728080
Vancouver
Gu Y, Zhang B. Dupilumab: A Potential Option for Young Children With Alopecia Areata and Atopic Features. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/4728080
BibTeX
@article{Gu2026,
author = {Gu, Ying and Zhang, Bin},
title = {Dupilumab: A Potential Option for Young Children With Alopecia Areata and Atopic Features},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/4728080}
}
EUVIMED